Cargando…

Bioactivities of EF24, a Novel Curcumin Analog: A Review

Curcumin is an attractive agent due to its multiple bioactivities. However, the low oral bioavailability and efficacy profile hinders its clinical application. To improve the bioavailability, many analogs of curcumin have been developed, among which EF24 is an excellent representative. EF24 has enha...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Yonghan, Li, Wen, Hu, Guangrong, Sun, Hui, Kong, Qingpeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297553/
https://www.ncbi.nlm.nih.gov/pubmed/30619754
http://dx.doi.org/10.3389/fonc.2018.00614
_version_ 1783381185480622080
author He, Yonghan
Li, Wen
Hu, Guangrong
Sun, Hui
Kong, Qingpeng
author_facet He, Yonghan
Li, Wen
Hu, Guangrong
Sun, Hui
Kong, Qingpeng
author_sort He, Yonghan
collection PubMed
description Curcumin is an attractive agent due to its multiple bioactivities. However, the low oral bioavailability and efficacy profile hinders its clinical application. To improve the bioavailability, many analogs of curcumin have been developed, among which EF24 is an excellent representative. EF24 has enhanced bioavailability over curcumin and shows more potent bioactivity, including anti-cancer, anti-inflammatory, and anti-bacterial. EF24 inhibits tumor growth by inducing cell cycle arrest and apoptosis, mainly through its inhibitory effect on the nuclear factor kappa B (NF-κB) pathway and by regulating key genes through microRNA (miRNA) or the proteosomal pathway. Based on the current structure, more potent EF24 analogs have been designed and synthesized. However, some roles of EF24 remain unclear, such as whether it induces or inhibits reactive oxygen species (ROS) production and whether it stimulates or inhibits the mitogen activated kinase-like protein (MAPK) pathway. This review summarizes the known biological and pharmacological activities and mechanisms of action of EF24.
format Online
Article
Text
id pubmed-6297553
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-62975532019-01-07 Bioactivities of EF24, a Novel Curcumin Analog: A Review He, Yonghan Li, Wen Hu, Guangrong Sun, Hui Kong, Qingpeng Front Oncol Oncology Curcumin is an attractive agent due to its multiple bioactivities. However, the low oral bioavailability and efficacy profile hinders its clinical application. To improve the bioavailability, many analogs of curcumin have been developed, among which EF24 is an excellent representative. EF24 has enhanced bioavailability over curcumin and shows more potent bioactivity, including anti-cancer, anti-inflammatory, and anti-bacterial. EF24 inhibits tumor growth by inducing cell cycle arrest and apoptosis, mainly through its inhibitory effect on the nuclear factor kappa B (NF-κB) pathway and by regulating key genes through microRNA (miRNA) or the proteosomal pathway. Based on the current structure, more potent EF24 analogs have been designed and synthesized. However, some roles of EF24 remain unclear, such as whether it induces or inhibits reactive oxygen species (ROS) production and whether it stimulates or inhibits the mitogen activated kinase-like protein (MAPK) pathway. This review summarizes the known biological and pharmacological activities and mechanisms of action of EF24. Frontiers Media S.A. 2018-12-11 /pmc/articles/PMC6297553/ /pubmed/30619754 http://dx.doi.org/10.3389/fonc.2018.00614 Text en Copyright © 2018 He, Li, Hu, Sun and Kong. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
He, Yonghan
Li, Wen
Hu, Guangrong
Sun, Hui
Kong, Qingpeng
Bioactivities of EF24, a Novel Curcumin Analog: A Review
title Bioactivities of EF24, a Novel Curcumin Analog: A Review
title_full Bioactivities of EF24, a Novel Curcumin Analog: A Review
title_fullStr Bioactivities of EF24, a Novel Curcumin Analog: A Review
title_full_unstemmed Bioactivities of EF24, a Novel Curcumin Analog: A Review
title_short Bioactivities of EF24, a Novel Curcumin Analog: A Review
title_sort bioactivities of ef24, a novel curcumin analog: a review
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297553/
https://www.ncbi.nlm.nih.gov/pubmed/30619754
http://dx.doi.org/10.3389/fonc.2018.00614
work_keys_str_mv AT heyonghan bioactivitiesofef24anovelcurcuminanalogareview
AT liwen bioactivitiesofef24anovelcurcuminanalogareview
AT huguangrong bioactivitiesofef24anovelcurcuminanalogareview
AT sunhui bioactivitiesofef24anovelcurcuminanalogareview
AT kongqingpeng bioactivitiesofef24anovelcurcuminanalogareview